eISSN: 2449-8238
ISSN: 2392-1099
Clinical and Experimental Hepatology
Current issue Archive Manuscripts accepted About the journal Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
4/2018
vol. 4
 
Share:
Share:
more
 
 
abstract:
Original paper

N-acetylcysteine protects hepatocytes from hypoxia-related cell injury

Jan Heil, Daniel Schultze, Peter Schemmer, Helge Bruns

Clin Exp HEPATOL 2018; 4, 4: 260–266
Online publish date: 2018/12/03
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Aim of the study
Hepatocyte transplantation has been discussed as an alternative to liver transplantation in selected cases of acute and chronic liver failure and metabolic diseases. Immediately after infusion of hepatocytes, hypoxia-related cell injury is inevitable. N-acetylcysteine (NAC) has been suggested to attenuate hypoxic damage. This study’s objective was to evaluate NAC’s protective effect in a model of hypoxia-related hepatocyte injury.

Material and methods
HepG2 cells were used as a model for hepatocytes and were cultured under standardized hypoxia or normoxia for 24 hours with or without NAC. Growth kinetics were monitored using trypan blue staining. The activation of apoptotic pathways was measured using quantitative real-time PCR for Bcl-2/Bax and p53. The proportions of vital, apoptotic and necrotic cells were verified by fluorescence activated cell sorting using annexin V-labelling. The expression of hypoxia inducible factor 1 (HIF-1) was measured indirectly using its downstream target vascular endothelial growth factor A (VEGF-A).

Results
After NAC, cell proliferation increased under both hypoxia and normoxia by 528% and 320% (p < 0.05), while VEGF-A expression decreased under normoxia by 67% and 37% (p < 0.05). Compared to cells treated without NAC under hypoxia, the Bcl-2/Bax ratio increased significantly in cells treated with NAC. This finding was confirmed by an increased number of vital cells in FACS analysis.

Conclusions
NAC protects hepatocytes from hypoxic injury and ultimately activates anti-apoptotic pathways.

keywords:

hypoxia, N-acetylcysteine, HepG2, hepatocyte transplantation

references:
Jorns C, Ellis EC, Nowak G, et al. Hepatocyte transplantation for inherited metabolic diseases of the liver. J Intern Med 2012; 272: 201-223.
Jochmans I, van Rosmalen M, Pirenne J, Samuel U. Adult liver allocation in Eurotransplant. Transplantation 2017; 101: 1542-1550.
Gupta S, Wilson JM, Chowdhury JR. Hepatocyte transplantation: development of new systems for liver repopulation and gene therapy. Semin Liver Dis 1992; 12: 321-331.
Mitry RR, Hughes RD, Aw MM, et al. Human hepatocyte isolation and relationship of cell viability to early graft function. Cell Transplant 2003; 12: 69-74.
Lange C, Bassler P, Lioznov MV, et al. Liver-specific gene expression in mesenchymal stem cells is induced by liver cells. World J Gastroenterol 2005; 11: 4497-4504.
Lange C, Bassler P, Lioznov MV, et al. Hepatocytic gene expression in cultured rat mesenchymal stem cells. Transplant Proc 2005; 37: 276-279.
Lange C, Schroeder J, Stute N, et al. High-potential human mesenchymal stem cells. Stem Cells Dev 2005; 14: 70-80.
Groth A, Ottinger S, Kleist C, et al. Evaluation of porcine mesenchymal stem cells for therapeutic use in human liver cancer. Int J Oncol 2012; 40: 391-401.
Mallanna SK, Duncan SA. Differentiation of hepatocytes from pluripotent stem cells. Curr Protoc Stem Cell Biol 2013; 26: Unit 1G 4.
Hansel MC, Gramignoli R, Skvorak KJ, et al. The history and use of human hepatocytes for the treatment of liver diseases: the first 100 patients. Curr Protoc Toxicol 2014; 62: 14.12.1-14.12.23.
Groth CG, Arborgh B, Bjorken C, et al. Correction of hyperbilirubinemia in the glucuronyltransferase-deficient rat by intraportal hepatocyte transplantation. Transplant Proc 1977; 9: 313-316.
Gupta S, Bhargava KK, Novikoff PM. Mechanisms of cell engraftment during liver repopulation with hepatocyte transplantation. Semin Liver Dis 1999; 19: 15-26.
Fox IJ, Chowdhury JR, Kaufman SS, et al. Treatment of the Crigler-Najjar syndrome type I with hepatocyte transplantation.
N Engl J Med 1998; 338: 1422-1426.
Fisher RA, Strom SC. Human hepatocyte transplantation: worldwide results. Transplantation 2006; 82: 441-449.
Vacanti JP, Kulig KM. Liver cell therapy and tissue engineering for transplantation. Semin Pediatr Surg 2014; 23: 150-155.
Ho CM, Chen YH, Chien CS, et al. Transplantation speed offers early hepatocyte engraftment in acute liver injured rats: A translational study with clinical implications. Liver Transpl 2015; 21: 652-661.
Ibars EP, Cortes M, Tolosa L, et al. Hepatocyte transplantation program: Lessons learned and future strategies. World J Gastroenterol 2016; 22: 874-886.
Stephenne X, Najimi M, Sokal EM. Hepatocyte cryopreservation: is it time to change the strategy? World J Gastroenterol 2010; 16: 1-14.
Smith MK, Peters MC, Richardson TP, et al. Locally enhanced angiogenesis promotes transplanted cell survival. Tissue Eng 2004; 10: 63-71.
van Tonder JJ, Gulumian M, Cromarty AD, Steenkamp V. In vitro effect of N-acetylcysteine on hepatocyte injury caused by dichlorodiphenyltrichloroethane and its metabolites. Hum Exp Toxicol 2014; 33: 41-53.
Shimizu MH, Gois PH, Volpini RA, et al. N-acetylcysteine protects against star fruit-induced acute kidney injury. Ren Fail 2017; 39: 193-202.
Yu W, Guo F, Song X. Effects and mechanisms of pirfenidone, prednisone and acetylcysteine on pulmonary fibrosis in rat idiopathic pulmonary fibrosis models. Pharm Biol 2017; 55: 450-455.
da Costa M, Bernardi J, Costa L, et al. N-acetylcysteine treatment attenuates the cognitive impairment and synaptic plasticity loss induced by streptozotocin. Chem Biol Interact 2017; 272: 37-46.
Liao CY, Chung CH, Wu CC, et al. Protective effect of N-acetylcysteine on progression to end-stage renal disease: Necessity for prospective clinical trial. Eur J Intern Med 2017; 44: 67-73.
Čolović MB, Vasić VM, Djuric DM, Krstić DZ. Sulphur-containing amino acids: protective role against free radals and heavy metals. Curr Med Chem 2018; 25: 324-335.
Bartekova M, Barancik M, Ferenczyova K, Dhalla NS. Beneficial effects of N-acetylcysteine and N-mercaptopropionylglycine on ischemia reperfusion injury in the heart. Curr Med Chem 2018; 25: 355-366.
Zafarullah M, Li WQ, Sylvester J, Ahmad M. Molecular mechanisms of N-acetylcysteine actions. Cell Mol Life Sci 2003; 60: 6-20.
Polson J, Lee WM, American Association for the Study of Liver D. AASLD position paper: the management of acute liver failure. Hepatology 2005; 41: 1179-1197.
Saito C, Zwingmann C, Jaeschke H. Novel mechanisms of protection against acetaminophen hepatotoxicity in mice by glutathione and N-acetylcysteine. Hepatology 2010; 51: 246-254.
Lee WM, Hynan LS, Rossaro L, et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology 2009; 137: 856-864.
Sayed E, Gaballah K, Younis E, et al. The effect of intravenous infusion of N-acetyl cysteine in cirrhotic patients undergoing liver resection: A randomized controlled trial. J Anaesthesiol Clin Pharmacol 2017; 33: 450-456.
Borlak J, van Bömmel F, Berg T. N-acetylcysteine and prednisolone treatment improved serum biochemistries in suspected flupirtine cases of severe idiosyncratic liver injury. Liver Int 2018; 38: 365-376.
Zwingmann C, Bilodeau M. Metabolic insights into the hepatoprotective role of N-acetylcysteine in mouse liver. Hepatology 2006; 43: 454-463.
Koch A, Trautwein C. N-acetylcysteine on its way to a broader application in patients with acute liver failure. Hepatology 2010; 51: 338-340.
Jones AL. Mechanism of action and value of N-acetylcysteine in the treatment of early and late acetaminophen poisoning: a critical review. J Toxicol Clin Toxicol 1998; 36: 277-285.
Hogquist KA, Nett MA, Unanue ER, Chaplin DD. Interleukin 1 is processed and released during apoptosis. Proc Natl Acad Sci U S A 1991; 88: 8485-8489.
Harrison PM, Wendon JA, Gimson AE, et al. Improvement by acetylcysteine of hemodynamics and oxygen transport in fulminant hepatic failure. N Engl J Med 1991; 324: 1852-1857.
Jegatheeswaran S, Siriwardena AK. Experimental and clinical evidence for modification of hepatic ischaemia-reperfusion injury by N-acetylcysteine during major liver surgery. HPB (Oxford) 2011; 13: 71-78.
Fiegel HC, Bruns H, Hoper C, et al. Cell growth and differentiation of different hepatic cells isolated from fetal rat liver in vitro. Tissue Eng 2006; 12: 123-130.
Oh SH, Lim SC. A rapid and transient ROS generation by cadmium triggers apoptosis via caspase-dependent pathway in HepG2 cells and this is inhibited through N-acetylcysteine-mediated catalase upregulation. Toxicol Appl Pharmacol 2006; 212: 212-223.
Wu XY, Luo AY, Zhou YR, Ren JH. N-acetylcysteine reduces oxidative stress, nuclear factorkappaB activity and cardiomyocyte apoptosis in heart failure. Mol Med Rep 2014; 10: 615-624.
Roy MJ, Vom A, Czabotar PE, Lessene G. Cell death and the mitochondria: therapeutic targeting of the BCL-2 family-driven pathway. Br J Pharmacol 2014; 171: 1973-1987.
Koch S, Claesson-Welsh L. Signal transduction by vascular endothelial growth factor receptors. Cold Spring Harb Perspect Med 2012; 2: a006502.
Sceneay J, Liu MC, Chen A, et al. The antioxidant N-acetylcysteine prevents HIF-1 stabilization under hypoxia in vitro but does not affect tumorigenesis in multiple breast cancer models in vivo. PLoS One 2013; 8: e66388.
Roy H, Bhardwaj S, Yla-Herttuala S. Biology of vascular endothelial growth factors. FEBS Lett 2006; 580: 2879-2887.
FEATURED PRODUCTS
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe